ArticleJournal of neurology2013
Cerebrospinal fluid biomarkers in Alzheimer's disease, vascular dementia and ischemic stroke patients: a critical analysis.
Article in Journal of neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Cerebrospinal Fluid Biomarkers for Diagnosis and the Prognostication of Acute Ischemic Stroke: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Morphometric imaging biomarker identifies Alzheimer's disease even among mixed dementia patients.Scientific reports · 2022Trial
- CSF Amyloid and Tau Biomarkers Distinguish Mixed from Vascular Dementia by Identifying Alzheimer's Disease Co-Pathology.Medicina (Kaunas, Lithuania) · 2026Article
- The Blood-Cerebrospinal Fluid Barrier Dysfunction in Brain Disorders and Stroke: Why, How, What For?Neuromolecular medicine · 2024Review
- Body fluid multiomics in 3PM-guided ischemic stroke management: health risk assessment, targeted protection against health-to-disease transition, and cost-effective personalized approach are envisaged.The EPMA journal · 2024Review
- Association of oxidative stress and inflammatory metabolites with Alzheimer's disease cerebrospinal fluid biomarkers in mild cognitive impairment.Alzheimer's research & therapy · 2024Article
- Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study.Alzheimer's research & therapy · 2024Article
- Neurodegeneration and Vascular Burden on Cognition After Midlife: A Plasma and Neuroimaging Biomarker Study.Frontiers in human neuroscience · 2021Article
- Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease.Alzheimer's research & therapy · 2020Article
- Distress in neurocognitive disorders due to Alzheimer's disease and stroke.Experimental and therapeutic medicine · 2020Article
- Update on the Neurobiology of Vascular Cognitive Impairment: From Lab to Clinic.International journal of molecular sciences · 2020Review
- Article
- Transient increase in CSF GAP-43 concentration after ischemic stroke.BMC neurology · 2018Article
- Exosomes in Acquired Neurological Disorders: New Insights into Pathophysiology and Treatment.Molecular neurobiology · 2018Review
- Visualization of ischemic stroke-related changes onEJNMMI research · 2018Article
- Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease.Molecular neurobiology · 2018Article
- Update on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease.Journal of Alzheimer's disease : JAD · 2018Review
- Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke.BMC neurology · 2017Article
- Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases.Scientific reports · 2017Article
- Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease.Neurology and therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular factors are thought to contribute to the development of disease pathology in neurodegenerative dementia such as Alzheimer's disease (AD). Another entity, called vascular dementia (VaD), comprises a less defined group of dementia patients having various vascular diseases that especially emerge in the elderly population and require valid options for examination and differential diagnosis. In the context of a retrospective study, we analyzed the cerebrospinal fluid (CSF) biomarkers t-tau, p-tau and Aß42 of a total of 131 patients with AD (n = 47), mild cognitive impairment (MCI) (n = 22), VaD (n = 44) and stroke (n = 18). We found a remarkable alteration in CSF biomarker profile in AD, VaD and in acute ischemic events. CSF profile in AD patients was altered in a very similar way as in stroke patients, without statistical differences. In stroke, increase depend largely on size and duration after the initial event. Total tau levels were useful to differ between VaD and stroke. Aß42 decreased in a similar way in AD, VaD and stroke and had a trend to lower levels in MCI but not in controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.